Abstract
Multiple sclerosis (MS) research addressed several challenges in 2014, including progressive MS. Despite advances in other forms of MS, there are no approved treatments for progressive MS because of the scarcity of reliable methods to test when, how, and why MS progresses. Nonetheless, post-hoc analyses of placebo-controlled trials1,2 suggest that a subset of patients with progressive MS might benefit from immune-directed therapies, which are usually effective in the management of relapsing–remitting MS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
